What are the recommended medications for treating anxiety in Intensive Care Unit (ICU) patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Medications for Treating Anxiety in ICU Patients

Dexmedetomidine should be used as the first-line medication for treating anxiety in ICU patients rather than benzodiazepines, as it is associated with lower delirium prevalence and better clinical outcomes. 1

First-Line Medications

Alpha-2 Agonist

  • Dexmedetomidine
    • Dosing: Initial infusion of 0.2-0.7 μg/kg/hr without loading dose in hemodynamically unstable patients 1
    • Benefits:
      • Shorter duration of mechanical ventilation
      • Reduced ICU length of stay
      • Lower incidence of delirium compared to benzodiazepines
      • Maintains light sedation levels
      • Allows for patient communication and cooperation
    • Cautions:
      • Monitor for bradycardia and hypotension
      • May cause hypertension with loading doses
      • Can lead to withdrawal symptoms (nausea, vomiting, agitation) if abruptly discontinued after prolonged use

Second-Line Medications

Non-Benzodiazepine Sedatives

  • Propofol
    • Dosing: 5-50 μg/kg/min 1
    • Benefits:
      • Rapid onset (1-2 minutes)
      • Short half-life allowing quick titration
      • No active metabolites
    • Cautions:
      • Can cause hypotension, respiratory depression
      • Risk of hypertriglyceridemia and propofol infusion syndrome
      • Pain at injection site

Benzodiazepines (use only when specifically indicated)

  • Midazolam

    • Dosing: 0.02-0.1 mg/kg/hr 2
    • Use primarily for:
      • Alcohol withdrawal
      • Benzodiazepine withdrawal
      • Short-term sedation only
    • Cautions:
      • Associated with increased delirium risk
      • Respiratory depression
      • Hypotension
  • Lorazepam

    • Dosing: 0.01-0.1 mg/kg/hr (≤10 mg/hr) 3
    • Use primarily for:
      • Alcohol withdrawal
      • Seizure control
    • Cautions:
      • Longer half-life (8-15 hours)
      • Risk of propylene glycol-related acidosis with prolonged use
      • Associated with increased delirium risk

Medication Selection Algorithm

  1. Assess for specific indications:

    • If patient has alcohol withdrawal → Benzodiazepines preferred
    • If patient has seizures → Lorazepam may be indicated
    • For all other anxiety indications → Start with dexmedetomidine
  2. Consider hemodynamic status:

    • If hemodynamically unstable → Avoid loading doses of dexmedetomidine
    • If hypotensive → Use caution with propofol and benzodiazepines
    • If bradycardic → Use caution with dexmedetomidine
  3. Consider duration of therapy needed:

    • Short-term sedation → Dexmedetomidine or propofol
    • If prolonged sedation anticipated → Implement daily sedation interruption protocols

Implementation Recommendations

  • Use validated sedation scales (RASS or SAS) to monitor sedation depth 1
  • Implement analgesia-first sedation approach before using anxiolytics 1
  • Maintain lighter levels of sedation when possible 1
  • Use sedation protocols and daily checklists to integrate pain, agitation, and delirium management 1
  • Implement early mobilization within the first few days in ICU to reduce anxiety and delirium 1
  • Consider ICU diaries to reduce anxiety, depression, and PTSD symptoms 1

Important Considerations

  • Prolonged use of any sedative requires gradual weaning to prevent withdrawal symptoms
  • Benzodiazepines are associated with increased delirium risk, longer mechanical ventilation, and longer ICU stays 1
  • Identify and treat underlying causes of anxiety (pain, hypoxemia, hypoglycemia) before initiating anxiolytics
  • Psychological interventions should be offered alongside pharmacological treatment for anxiety 1

Withdrawal Prevention

For patients receiving prolonged sedation:

  • Gradually taper opioids and sedatives over several days
  • Monitor for withdrawal symptoms:
    • Opioid withdrawal: sweating, mydriasis, tachycardia, hypertension, anxiety
    • Benzodiazepine withdrawal: anxiety, agitation, tremors, insomnia, seizures
    • Dexmedetomidine withdrawal: nausea, vomiting, agitation (within 24-48 hours)

By prioritizing dexmedetomidine over benzodiazepines and maintaining light sedation levels, ICU patients will experience improved outcomes including reduced delirium, shorter mechanical ventilation duration, and decreased ICU length of stay.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.